RESUMEN
Atopic dermatitis (AD) is an inflammatory skin disease that frequently occurs in adolescents. Although there are many treatment options, the challenge for clinicians is finding an effective long-term drug for AD with a favorable safety profile. The purpose of this review is to describe the role of tralokinumab, an IL-13 inhibitor, in treating adolescent AD. The clinical efficacy and safety of tralokinumab were established in clinical trials for adults with moderate-to-severe AD. Based on the results of these trials and the preliminary results of trials conducted on adolescents with AD, tralokinumab effectively alleviates symptoms with tolerable adverse effects. Extending the use of tralokinumab to adolescents with moderate-to-severe AD seems promising for the future.
Atopic dermatitis (AD) is a common long-term skin disease characterized by scaling, redness, itching, pain and sleep disturbances. Fortunately, many treatment options are available depending on the severity of the disease. In this article, the authors describe the potential role of tralokinumab, a drug that blocks a key signal in the immune system that causes AD. The results of recent studies and trials imply that tralokinumab can be effective in providing at least short-term relief of AD symptoms in patients unresponsive to other treatments. So far, it has had an acceptable overall safety profile. The future of tralokinumab treatment in the adolescent population seems promising.
